• news.cision.com/
  • Abliva/
  • Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”
English

Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”

Report this content

Lund, Sweden, 11 December 2018 – NeuroVive Pharmaceutical AB(publ)("NeuroVive" or "the Company") announces adjustment of the following dates in the press release, published on December 10, 2018:

  • Last day of trading in shares including the right to participate in the Rights Issue
    with preferential right;
  • First day for trading in shares without the right to participate in the Rights issue
    with preferential rights; and
  • Record date for the receipt of subscription rights and right to participate in
    the Rights issue with preferential rights.

Below are the adjusted dates:

Preliminary timetable for the Rights issue (all dates refer to 2019)

Thursday, 17 January            Last day of trading in shares including the right to participate
                                               in the Rights Issue with preferential right

Friday, 18 January                 First day for trading in shares without the right to participate
                                               in the Rights issue with preferential rights

Monday, 21 January             Record date for the receipt of subscription rights and right to
                                             participate in the Rights issue with preferential rights

In addition to these adjustments, the information communicated in the press release on December 10, 2018 is still applicable.

The information was submitted for publication, through the agency of the contact person set out below, at 10.00 a.m. CET on 11 December 2018.

For more information please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/ 

About NeuroVive 
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

Subscribe

Documents & Links